Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects (Q84927753)

From Wikidata

Jump to navigation Jump to search

scientific article published on 08 September 2011

Language	Label	Description	Also known as
English	Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects	scientific article published on 08 September 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects (English)

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Titti Martinsson-Niskanen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Rikke Riisbro

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Leonard Larsson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Lena Winstedt

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Yvonne Stenberg

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Steve Pakola

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Jean-Marie Stassen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Steven Glazer

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21906811

12 December 2024

publication date

8 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

full work available at URL

https://api.elsevier.com/content/article/PII:S0149291811005455?httpAccept=text/xml

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

https://api.elsevier.com/content/article/PII:S0149291811005455?httpAccept=text/plain

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Clinical Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

33

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

1142-1149

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

2

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Sorafenib in advanced clear-cell renal-cell carcinoma

3

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

4

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

5

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

6

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

7

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma.

8

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy

9

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence

10

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

11

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid

12

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

15

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development

16

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

17

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

18

1 reference

10.1016/J.CLINTHERA.2011.08.007

https://api.crossref.org/works/10.1016/J.CLINTHERA.2011.08.007

12 December 2024

Identifiers

10.1016/J.CLINTHERA.2011.08.007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21906811 AND SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84927753&oldid=2286256076"